Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest announcement is out from Next Science Ltd ( (AU:NXS) ).
Next Science Ltd is currently involved in legal proceedings initiated by former employee Michael Morello, who has filed a derivative complaint in Florida alleging breaches of fiduciary duties and mismanagement. The complaint raises concerns about the FDA approval and safety measures of Next Science’s products, specifically its XBIO™ technology and XPERIENCE™ surgical solution. In response, Next Science asserts its products are safe, FDA-approved, and has engaged US attorneys to handle the litigation, while committing to an independent investigation into the allegations.
More about Next Science Ltd
Next Science is a medical technology company based in Sydney, Australia, with a research and development center in Florida, USA. Founded in 2012, the company focuses on developing and commercializing its proprietary XBIO™ technology, which targets the reduction of biofilm-based infections in healthcare. The technology is known for its non-toxic and effective eradication of both biofilm-based and free-floating bacteria, and the company holds full patent rights to this intellectual property.
YTD Price Performance: -8.57%
Average Trading Volume: 20,115
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $21M
For a thorough assessment of NXS stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Walmart (NYSE:WMT) Hits Mar-a-Lago to Talk Tariffs
- Ford (NYSE:F) Finds Battery Troubles at Every Turn
- Intel (NASDAQ:INTC) Makes Appearances in More Laptops, Cars
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
